Cue Biopharma, is a clinical-stage biopharmaceutical company developing biologic drugs to treat various cancers, chronic infectious diseases, and autoimmune disorders by selective modulation of the human immune system. The company is best known for its lead drug, CUE-101, a fusion protein biologic in Phase 1b clinical trial, designed to activate antigen-specific T cells for human papilloma virus-driven cancers. Cue Bio has numerous partnership agreements with Merck Sharp & Dohme Corp., LG Chem Life Sciences, and Albert Einstein College of Medicine to collaborate on the development of their novel biologics.